Literature DB >> 9661637

Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells.

M V Blagosklonny1, P Giannakakou, M Wojtowicz, L Y Romanova, K B Ain, S E Bates, T Fojo.   

Abstract

We investigated the p53 status and the ability of exogenous wildtype (wt) p53 to affect chemosensitivity in three anaplastic thyroid carcinoma cell lines (BHT-101, SW-1736, and KAT-4). All three cell lines had nonfunctional p53. Treatment with mitomycin C or adriamycin did not result in accumulation of p53 or induction of p21WAF1/CIP1 or Mdm-2 and did not cause Rb dephosphorylation. BHT-101 and KAT-4 cells had mutant p53. SW-1736 cells were functionally mutant because of marked down-regulation of wt p53 messenger ribonucleic acid, representing a novel mechanism of p53 dysfunction. Infection with a p53-expressing adenovirus (Ad-p53) induced high levels of p21 and Mdm-2 proteins. In BHT-101 cells, induction of p21 and Mdm-2 was evident 10 h after infection. In KAT-4 cells, induction of p21 and Mdm-2 was observed 1 day after infection, and continued to increase over the ensuing 24 h. SW-1736 cells demonstrated intermediate kinetics. Sensitivity to the cytotoxic effect of Ad-p53 paralleled the kinetics of p21/Mdm-2 induction. BHT-101 cells were most sensitive to killing by Ad-p53, with an IC50 of less than 2 multiplicity of infection; SW-1736 cells were intermediate in sensitivity; KAT-4 cells were resistant. All three cell lines became more sensitive to adriamycin after wt p53 expression, with a 10-fold decrease in IC50 values. The latter observation may make a combination of wt p53 and chemotherapeutic drugs an attractive modality for treating anaplastic thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9661637     DOI: 10.1210/jcem.83.7.4984

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

1.  Angio-adaptation in unloaded skeletal muscle: new insights into an early and muscle type-specific dynamic process.

Authors:  Emilie Roudier; Charlotte Gineste; Alexandra Wazna; Kooroush Dehghan; Dominique Desplanches; Olivier Birot
Journal:  J Physiol       Date:  2010-09-27       Impact factor: 5.182

2.  Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma.

Authors:  W Voigt; T Kegel; M Weiss; T Mueller; H Simon; H J Schmoll
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

3.  Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF.

Authors:  Gangjian Qin; Raj Kishore; Christine M Dolan; Marcy Silver; Andrea Wecker; Corinne N Luedemann; Tina Thorne; Allison Hanley; Cynthia Curry; Lindsay Heyd; Deepika Dinesh; Marianne Kearney; Fabio Martelli; Toshinori Murayama; David A Goukassian; Yan Zhu; Douglas W Losordo
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-11       Impact factor: 11.205

4.  Bcl-2 and p53 expression in insular and in well-differentiated thyroid carcinomas with an insular pattern.

Authors:  H E Peştereli; M Oğüş; N Oren; G Karpuzoğlu; T Kerpuzoğlu
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

Review 5.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

Review 6.  Surgical options in undifferentiated thyroid carcinoma.

Authors:  Brian Hung-Hin Lang; Chung-Yau Lo
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

7.  Enlarging neck masses in the elderly - Histological and surgical considerations.

Authors:  M D O'Sullivan; K S McAnena; C Egan; P S Waters; P J McCann; M J Kerin
Journal:  Int J Surg Case Rep       Date:  2013-01-17

Review 8.  Conditionally replicating adenoviruses for cancer treatment.

Authors:  Youssef Jounaidi; Joshua C Doloff; David J Waxman
Journal:  Curr Cancer Drug Targets       Date:  2007-05       Impact factor: 3.428

9.  PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer.

Authors:  Daniela De Martino; Emrullah Yilmaz; Arturo Orlacchio; Michela Ranieri; Ke Zhao; Antonio Di Cristofano
Journal:  Cancer Lett       Date:  2018-09-19       Impact factor: 8.679

10.  Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China.

Authors:  Guangyu Ma; Hideaki Shimada; Kenzo Hiroshima; Yuji Tada; Nobuo Suzuki; Masatoshi Tagawa
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.